JWH-175

JWH-175 is a synthetic cannabinoid from the JWH series. It was developed by the team led by John W. Huffman, an organic chemist at Clemson University. JWH-175 is a potent and selective ligand for the cannabinoid receptor CB2, with a binding affinity of 2.1 nM, making it one of the most potent compounds in the JWH series.

History

The JWH series was developed in the mid-1990s by Huffman and his team in an effort to create a new class of cannabinoids. The series includes over 100 different compounds, each with varying affinities for the CB1 and CB2 receptors. JWH-175 is one of the most potent compounds in the series, with a high affinity for the CB2 receptor.

Pharmacology

JWH-175 is a potent and selective ligand for the CB2 receptor, with a binding affinity of 2.1 nM. This makes it one of the most potent compounds in the JWH series. The CB2 receptor is primarily found in the immune system, and is less prevalent in the central nervous system. The exact effects of JWH-175 on the human body are not fully understood, as most research has been conducted in vitro or in animal models.

Legal Status

The legal status of JWH-175 varies by country. In the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess without a license. In other countries, it may be legal or regulated under analogue laws.

See Also

• JWH-018
• JWH-073
• JWH-200
• Synthetic cannabinoids
• Cannabinoid receptor